What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The EMERALD trial, a Phase 3 study, demonstrated a moderate benefit of elacestrant over standard care, with a median progression-free survival of 8.6 months compared to 1.9 months for the physician’s choice arm. However, the evidence is based on indirect comparisons and post-hoc subgroup analyses, leading to some uncertainty regarding the robustness of these findings.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for elacestrant fall within the acceptable range of £20,000 to £30,000 per QALY gained, which is considered defensible. The committee acknowledged the uncertainties but concluded that the ICERs were acceptable for both subgroups.
Is there quality-of-life evidence payers weigh? — Quality of life
While the document discusses the impact of the condition on patients’ lives, it does not provide specific data on HRQoL improvements associated with elacestrant. The evidence suggests potential benefits, but the lack of validated tools or significant statistical improvements limits the rating.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Elacestrant has a very good safety profile with mostly mild to moderate adverse events reported. The committee noted that the adverse effects were manageable and comparable to existing therapies, indicating a favorable tolerability.
Was the drug compared against what payers expect? — Comparator Selection
The document indicates that there are no direct comparisons between elacestrant and standard care, relying instead on indirect comparisons. While the committee acknowledged the use of relevant comparators, the lack of direct evidence limits the strength of the conclusions.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is largely representative of the intended patient population, focusing on postmenopausal women and men with specific mutations. However, there are some concerns regarding the generalizability of the findings to the broader population due to the narrow inclusion criteria.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Elacestrant is expected to fit well into existing treatment pathways with minimal adjustments required. The oral administration form is particularly advantageous, facilitating easier integration into routine clinical practice.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of elacestrant are manageable, with the potential for cost savings due to its oral administration and the expected reduction in hospital visits. The committee noted that the overall budget impact is aligned with Healthcare planning.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is primarily derived from the EMERALD trial, which is robust but has limitations due to the reliance on indirect comparisons and post-hoc analyses. The committee expressed concerns about the potential biases and uncertainties in the evidence.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties surrounding the clinical effectiveness and cost-effectiveness estimates due to the methodological limitations of the analyses. The committee noted that these uncertainties could impact the decision-making process.
